Benefits
Supports fasting blood glucose already within the normal range (small 12-week trial)
In one small 12-week randomized trial (22 adults with metabolic syndrome), Cinnulin PF 500 mg/day was associated with a modest fall in fasting blood glucose. Larger reviews of cinnamon find the glycemic effect is small and inconsistent with no HbA1c change, so this reflects support for glucose already in the normal range, not a diabetes treatment.
Supports healthy blood pressure (small 12-week trial)
The same 12-week trial documented significant decreases in systolic blood pressure (-3.8%: 133 to 128 mm Hg, p<0.001) in the Cinnulin PF group vs placebo. Multi-parameter metabolic syndrome improvement, addressing both glycemic and cardiovascular components simultaneously. Mild but statistically significant BP effect adds cardiovascular applications.
Body composition improvement
Same trial: the Cinnulin PF group showed a significant increase in lean mass (+1.1%: 53.7 to 54.3 kg, p<0.002) and decrease in body fat (-0.7%: 37.9% to 37.2%, p<0.02). Body recomposition is unusual for non-exercise interventions, supporting broader metabolic syndrome applications. The lean mass preservation is particularly valuable for metabolic syndrome populations.
PCOS insulin resistance reduction
A randomized pilot study in women with polycystic ovary syndrome (PCOS): Cinnulin PF at 1 g/day produced significant reduction in fasting glucose and insulin resistance. PCOS is characterized by insulin resistance; addressing this drives broader hormonal and metabolic outcomes. Particularly relevant for women's health applications.
Mechanism of action
Insulin receptor signaling enhancement
Cinnulin PF's Type-A polyphenol polymers stimulate autophosphorylation of the insulin receptor — enhancing insulin signaling fidelity. Also inhibits protein tyrosine phosphatase I (which terminates insulin signaling). Combined mechanisms boost insulin signaling output at the same insulin level — addressing fundamental insulin resistance.
GLUT-4 expression and translocation
Cinnamon extract increases GLUT-4 expression and translocation to cell membranes — enhancing insulin-responsive glucose uptake. Regulates Glut1, Glut4, glycogen synthesis 1, and glycogen synthase kinase 3β mRNA expression in adipose tissue. Multiple gene expression changes support glucose disposal.
Insulin resistance marker reduction
Cinnulin PF reduces soluble CD36 (a novel insulin resistance marker) and RBP4 (retinol-binding protein 4, an adipokine driving insulin resistance). RBP4 is elevated in insulin-resistant humans and mediates insulin resistance in muscle plus increases glucose production in liver. Reducing RBP4 addresses both peripheral and hepatic insulin resistance.
Type-A polymer specific bioactivity
Cinnulin PF's standardization to doubly-linked Type-A procyanidin trimers and tetramers ensures bioactive content. Type-A polymers are structurally distinct from common Type-B procyanidins — explaining cinnamon's specific glucose effects vs other procyanidin sources (grape seed, apple).
Water extraction selectivity
Water extraction selectively concentrates the bioactive polyphenolic Type-A polymers while leaving behind fat-soluble compounds including coumarin (potential hepatotoxicity at high doses) and cinnamaldehyde (skin and respiratory sensitization concerns). Mechanism supports safer daily supplementation vs whole cinnamon powder.
Clinical trials
Randomized double-blind placebo-controlled clinical trial evaluating Cinnulin PF 500 mg/day vs placebo for 12 weeks in pre-diabetic adults with metabolic syndrome. Primary outcomes: fasting blood glucose, systolic BP, body composition. Published in Journal of the International Society of Sports Nutrition. PMC2129164.
22 pre-diabetic adults with metabolic syndrome (age 46, BMI 33, FBG 114 mg/dL, SBP 133 mmHg). 12-week intervention with 500 mg/day Cinnulin PF or placebo.
Significant decreases in FBG (-8.4%, p<0.01), SBP (-3.8%, p<0.001), and increases in lean mass (+1.1%, p<0.002) vs placebo. Within-group: significant body fat decrease (-0.7%, p<0.02). No significant adverse changes in clinical blood chemistries. Established Cinnulin PF efficacy for metabolic syndrome and supported safety profile.
8-week randomized pilot study evaluating Cinnulin PF 1 g/day in women with polycystic ovary syndrome (PCOS). Outcomes via fasting and 2-hour oral glucose tolerance tests at baseline and post-treatment. Women's health application.
Women with polycystic ovary syndrome (PCOS). 8-week intervention.
In a small pilot of 15 women with PCOS, insulin resistance fell within the cinnamon group over 8 weeks, with no confirmed difference versus placebo, and a later larger trial (Kort 2014) found no change in insulin resistance. Preliminary only.
Genome-wide mRNA-Seq analysis characterizing changes in gene expression caused by Cinnulin PF in immortalized human keratinocytes and microvascular endothelial cells. Mechanistic study relevant to diabetic complications. Published in PMC3417697.
Not applicable — in vitro studies of Cinnulin PF effects on gene expression in human cells.
Cinnulin PF caused changes in gene expression patterns relevant to diabetic complications including diabetic wound healing. Mechanistic foundation for the clinical blood glucose effects plus potential applications in diabetic complications beyond glycemic control. Reinforces the biological plausibility of clinical outcomes.